JAMMU, Nov 17: Morepen Laboratories Limited is accelerating its strategic pivot toward high-value global pharmaceutical manufacturing, according to top company executives who highlighted rapid progress in contract manufacturing and facility expansion following the company’s second-quarter performance.
Rather than focusing solely on top-line numbers, Morepen’s leadership emphasized a deeper structural shift: moving its Contract Development and Manufacturing Organization (CDMO) business into commercial scale while expanding technical capabilities to capture complex international contracts.
Reflecting on this strategic evolution, Sushil Suri, Chairman and Managing Director, Morepen Laboratories Limited, noted that the company’s core segments are maturing simultaneously.
“Q2 marks another important step in Morepen’s transformation. CDMO has moved into meaningful commercial scale, our API portfolio is becoming more global and higher-value, and Medical Devices continues to grow strongly,” he stated.
He added that the company’s strengthened financial footing—with H1 FY27 EBITDA crossing Rs 200 crore—serves primarily as a springboard for long-term infrastructure and capability building.
“H1 FY27 EBITDA crossing Rs. 200 Cr gives us a significantly stronger base to invest in capacity, capability and future growth,” Mr. Sushil Suri said.
On the execution front, leadership confirmed that manufacturing expansion is outpacing initial timelines to keep up with customer commitments.
Sanjay Suri, Managing Director, Morepen Laboratories Limited, revealed that the first phase of capacity expansion has already reached 614 kilolitres (KL) ahead of schedule, with the next growth phase actively underway.
“Civil work has commenced for the next phase towards 800 KL, targeted for completion by Q2 FY28,” Sanjay Suri noted, underscoring the company’s focus on specialized manufacturing.
“Alongside scale, we are building capability in high-potency APIs and new technologies, while engaging with global pharmaceutical customers across additional CDMO development and manufacturing opportunities.”
Together, the leadership’s remarks underscore Morepen’s transition from a traditional domestic manufacturer into a specialized, technology-driven partner for global pharmaceutical innovators.